BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37011398)

  • 21. The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study.
    Getaneh AM; Heijnsdijk EAM; de Koning HJ
    Sci Rep; 2021 Jan; 11(1):1801. PubMed ID: 33469144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
    Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
    BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial-Prostate Cancer Secondary Screening in Sapienza (PROSA).
    Messina E; La Torre G; Pecoraro M; Pisciotti ML; Sciarra A; Poscia R; Catalano C; Panebianco V
    Eur Radiol; 2024 Jan; 34(1):204-213. PubMed ID: 37561183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
    Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
    JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implementation of multiparametric magnetic resonance imaging technology for evaluation of patients with suspicion for prostate cancer in the clinical practice setting.
    Shah PH; Patel VR; Moreira DM; George AK; Alom M; Kozel Z; Joshi V; Ben-Levi E; Villani R; Yaskiv O; Kavoussi LR; Vira M; Olsson CO; Rastinehad AR
    BJU Int; 2019 Feb; 123(2):239-245. PubMed ID: 30113138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy.
    Shakir NA; George AK; Siddiqui MM; Rothwax JT; Rais-Bahrami S; Stamatakis L; Su D; Okoro C; Raskolnikov D; Walton-Diaz A; Simon R; Turkbey B; Choyke PL; Merino MJ; Wood BJ; Pinto PA
    J Urol; 2014 Dec; 192(6):1642-8. PubMed ID: 25117476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial.
    Wallström J; Geterud K; Kohestani K; Maier SE; Månsson M; Pihl CG; Socratous A; Arnsrud Godtman R; Hellström M; Hugosson J
    Eur Radiol; 2021 Nov; 31(11):8692-8702. PubMed ID: 33890152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review.
    Moore CM; Robertson NL; Arsanious N; Middleton T; Villers A; Klotz L; Taneja SS; Emberton M
    Eur Urol; 2013 Jan; 63(1):125-40. PubMed ID: 22743165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis.
    Choi YH; Kang MY; Sung HH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Kim CK; Park BK; Lee HM
    Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seminar: Revisiting the value of PSA-based prostate cancer screening Essay No 5: Should men undergo MRI before prostate biopsy? (Pro).
    Maffei D; Giganti F; Moore CM
    Urol Oncol; 2023 Feb; 41(2):88-91. PubMed ID: 35871993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Systematic or targeted fusion-guided biopsy].
    Handke AE; Albers P; Schimmöller L; Bonekamp D; Asbach P; Schlemmer HP; Hadaschik BA; Radtke JP
    Urologie; 2023 May; 62(5):464-472. PubMed ID: 36941382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy.
    Bhat NR; Vetter JM; Andriole GL; Shetty AS; Ippolito JE; Kim EH
    Urology; 2019 Apr; 126():152-157. PubMed ID: 30580005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate.
    Costa DN; Goldberg K; Leon AD; Lotan Y; Xi Y; Aziz M; Freifeld Y; Margulis V; Raj G; Roehrborn CG; Hornberger B; Desai N; Bagrodia A; Francis F; Pedrosa I; Cadeddu JA
    Eur Urol Oncol; 2019 Jul; 2(4):397-404. PubMed ID: 31277776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re: Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
    Kenigsberg AP; Ahdoot M; Turkbey B; Pinto PA
    Eur Urol; 2023 Jun; 83(6):582-583. PubMed ID: 36907691
    [No Abstract]   [Full Text] [Related]  

  • 36. Re: Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
    Bratt O; Auvinen A
    Eur Urol; 2023 Apr; 83(4):370-371. PubMed ID: 36623950
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical and imaging tools in the early diagnosis of prostate cancer, a review.
    De Visschere P; Oosterlinck W; De Meerleer G; Villeirs G
    JBR-BTR; 2010; 93(2):62-70. PubMed ID: 20524513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen.
    Sonn GA; Chang E; Natarajan S; Margolis DJ; Macairan M; Lieu P; Huang J; Dorey FJ; Reiter RE; Marks LS
    Eur Urol; 2014 Apr; 65(4):809-15. PubMed ID: 23523537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI].
    Wang YM; Shang JW; Dong L; Liang LH; Zhao RZ; Liang C; Wang SQ; Xia W; Cheng G; Hua LX
    Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):942-947. PubMed ID: 37968079
    [No Abstract]   [Full Text] [Related]  

  • 40. The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men.
    Chiu PK; Lam TY; Ng CF; Teoh JY; Cho CC; Hung HY; Hong C; Roobol MJ; Chu WC; Wong SY; Sung JJ
    Asian J Androl; 2023 Nov; 25(6):674-679. PubMed ID: 37534902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.